UroGen Pharma (URGN) Operating Income Growth (5y) (2022 - 2026)

UroGen Pharma (URGN) Operating Income Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 UroGen Pharma 2.36 Bn 2.25 Bn 65.88 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 14.93%
Mar 31, 2026 4.95%
Dec 31, 2025 6.85%
Sep 30, 2025 1.22%
Jun 30, 2025 -5.44%
Mar 31, 2025 0.87%
Dec 31, 2024 7.04%
Sep 30, 2024 5.64%
Jun 30, 2024 -1.70%
Mar 31, 2024 -2.79%
Dec 31, 2023 9.46%
Sep 30, 2023 8.53%
Jun 30, 2023 3.56%
Mar 31, 2023 -10.08%
Dec 31, 2022 -14.83%
Sep 30, 2022 -126.56%
Jun 30, 2022 -25.75%
Mar 31, 2022 -44.07%